A long-awaited report into several high-profile resignations at Canada’s drug price regulator is calling for changes to how members of the government interact with the quasi-judicial body as well as the pharmaceutical industry.health committee report, made public this week, has 10 recommendations stemming from a string of events that seem to have indefinitely sidelined Ottawa’s attempts at drug price reform.
The step by Mr. Duclos was highly unusual and, according to e-mail exchanges and other documents later released at House health committee hearings, prompted three members of the PMPRB to resign. Some of the other recommendations in the newly published House of Commons report include a call for the government to spell out the mandate of the PMPRB; for members of the board to review its internal operating rules to avoid any misunderstandings; and for Ottawa to review how it enacts drug price regulatory reforms.